Revolution Medicines, Inc.
US ˙ NasdaqGS ˙ US76155X1000

Introduction

This page provides a comprehensive analysis of the known insider trading history of Third Rock Ventures II, L.P.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Third Rock Ventures II, L.P. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:JNCE / Jounce Therapeutics Inc 10% Owner 2,697,829
US:RVMD / Revolution Medicines, Inc. 10% Owner 0
10% Owner 885,104
US:ALNA / Allena Pharmaceuticals Inc 10% Owner 0
US:GBT / Global Blood Therapeutics Inc. 10% Owner 2,475,191
US:BPMC / Blueprint Medicines Corporation 10% Owner 3,453,753
US:SAGE / Sage Therapeutics, Inc. 10% Owner 2,892,916
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Third Rock Ventures II, L.P.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases RVMD / Revolution Medicines, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in RVMD / Revolution Medicines, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RVMD / Revolution Medicines, Inc. Insider Trades
Insider Sales RVMD / Revolution Medicines, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in RVMD / Revolution Medicines, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2021-06-04 RVMD Third Rock Ventures II, L.P. 164,996 30.2300 164,996 30.2300 4,987,829 342 14.5400 -2,588,787 -51.90
2021-06-03 RVMD Third Rock Ventures II, L.P. 378,117 30.2000 378,117 30.2000 11,419,133
2021-05-26 RVMD Third Rock Ventures II, L.P. 1,231,204 30.5300 1,231,204 30.5300 37,588,658
2021-05-25 RVMD Third Rock Ventures II, L.P. 135,000 30.9300 135,000 30.9300 4,175,550

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RVMD / Revolution Medicines, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Third Rock Ventures II, L.P. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2021-09-17 2021-09-15 4 JNCE Jounce Therapeutics, Inc.
Common Stock
J - Other X -1,750,000 2,697,829 -39.35
2021-06-14 2021-06-10 4 JNCE Jounce Therapeutics, Inc.
Common Stock
J - Other X -1,500,000 4,447,829 -25.22
2021-06-07 2021-06-04 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale -164,996 0 -100.00 30.23 -4,987,829
2021-06-07 2021-06-03 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale -378,117 164,996 -69.62 30.20 -11,419,133 4,982,879
2021-05-27 2021-05-25 4 JNCE Jounce Therapeutics, Inc.
Common Stock
S - Sale -552,520 5,947,829 -8.50 8.00 -4,420,160 47,582,632
2021-05-27 2021-05-26 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale -1,231,204 543,113 -69.39 30.53 -37,588,658 16,581,240
2021-05-27 2021-05-25 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale -135,000 1,774,317 -7.07 30.93 -4,175,550 54,879,625
2021-03-15 2021-03-11 4 JNCE Jounce Therapeutics, Inc.
Common Stock
J - Other X -1,250,000 6,500,349 -16.13
2021-03-03 2021-03-01 4 JNCE Jounce Therapeutics, Inc.
Common Stock
S - Sale -1,450,000 7,750,349 -15.76 11.75 -17,037,500 91,066,601
2020-11-23 2020-11-19 4 JNCE Jounce Therapeutics, Inc.
Common Stock
S - Sale -15,000 9,200,349 -0.16 7.00 -105,075 64,448,445
2020-11-19 2020-11-17 4 JNCE Jounce Therapeutics, Inc.
Common Stock
S - Sale -15,000 9,215,349 -0.16 7.25 -108,772 66,825,103
2020-11-13 2020-11-11 4 JNCE Jounce Therapeutics, Inc.
Common Stock
J - Other -1,000,000 9,230,349 -9.77
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Series B Preferred Stock
C - Conversion -1,909,317 0 -100.00
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Series C Preferred Stock
C - Conversion -49,879 0 -100.00
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Series B Preferred Stock
C - Conversion -342,505 0 -100.00
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Series A Preferred Stock
C - Conversion -8,220,641 0 -100.00
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Common Stock
C - Conversion 1,909,317 1,909,317
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Common Stock
C - Conversion 8,613,025 9,024,031 2,095.60
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2020-02-12 3 RVMD Revolution Medicines, Inc.
Common Stock
822,012
2018-03-07 2018-03-07 4 MYOK MyoKardia Inc
Common Stock
J - Other X -2,000,000 885,104 -69.32
2017-12-08 2017-12-06 4 MYOK MyoKardia Inc
Common Stock
J - Other X -2,000,000 2,885,104 -40.94
2017-11-06 2017-11-06 4 ALNA Allena Pharmaceuticals, Inc.
Series B Preferred Stock
C - Conversion -4,629,630 0 -100.00
2017-11-06 2017-11-06 4 ALNA Allena Pharmaceuticals, Inc.
Series A Preferred Stock
C - Conversion -6,122,448 0 -100.00
2017-11-06 2017-11-06 4 ALNA Allena Pharmaceuticals, Inc.
Common Stock
P - Purchase 215,000 2,790,964 8.35 14.00 3,010,000 39,073,496
2017-11-06 2017-11-06 4 ALNA Allena Pharmaceuticals, Inc.
Common Stock
C - Conversion 2,575,964 2,575,964
2017-09-29 2017-09-28 4 MYOK MyoKardia Inc
Common Stock
J - Other X -2,000,000 4,885,104 -29.05
2017-09-27 2017-09-26 4 MYOK MyoKardia Inc
Common Stock
S - Sale -400,000 6,885,104 -5.49 43.00 -17,200,000 296,059,472
2017-09-27 2017-09-25 4 MYOK MyoKardia Inc
Common Stock
S - Sale -201,400 7,285,104 -2.69 43.00 -8,660,200 313,259,472
2017-09-12 2017-09-11 4 MYOK MyoKardia Inc
Common Stock
S - Sale -20,000 57,651 -25.76 44.25 -885,080 2,551,287
2017-09-12 2017-09-08 4 MYOK MyoKardia Inc
Common Stock
S - Sale -900 7,486,504 -0.01 42.39 -38,149 317,337,932
2017-09-12 2017-09-08 4 MYOK MyoKardia Inc
Common Stock
S - Sale -200,350 7,487,404 -2.61 41.00 -8,214,350 306,983,564
2017-06-16 2017-06-14 4 GBT Global Blood Therapeutics, Inc.
Common Stock
J - Other X -1,000,000 2,475,191 -28.78
2017-05-19 2017-05-17 4 GBT Global Blood Therapeutics, Inc.
Common Stock
J - Other -1,000,000 3,475,191 -22.35
2017-05-19 2017-04-18 4 GBT Global Blood Therapeutics, Inc.
Common Stock
G - Gift -1,708 163,996 -1.03
2017-05-19 2017-04-11 4 GBT Global Blood Therapeutics, Inc.
Common Stock
G - Gift -50,000 165,704 -23.18
2017-04-06 2017-04-06 4 GBT Global Blood Therapeutics, Inc.
Common Stock
J - Other X -2,000,000 4,475,191 -30.89
2017-04-03 2017-03-30 4 MYOK MyoKardia Inc
Common Stock
J - Other X -850,000 7,687,754 -9.96
2017-03-06 2017-03-02 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale -10,900 146,208 -6.94 28.73 -313,146 4,200,410
2017-03-06 2017-03-02 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale -7,279 157,108 -4.43 27.69 -201,526 4,349,692
2017-03-06 2017-03-02 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale -27,115 164,387 -14.16 26.95 -730,803 4,430,558
2017-03-06 2017-03-02 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale -1,000,000 285,713 -77.78 25.50 -25,500,000 7,285,682
2017-03-06 2017-03-02 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale -1,000,000 285,713 -77.78 25.50 -25,500,000 7,285,682
2017-02-28 2017-02-27 4 BPMC Blueprint Medicines Corp
Common Stock
J - Other X -1,000,000 3,453,753 -22.45
2017-02-09 2017-02-07 4 BPMC Blueprint Medicines Corp
Common Stock
S - Sale -1,000,000 4,453,753 -18.34 35.28 -35,275,000 157,106,137
2017-02-03 2017-02-01 4 JNCE Jounce Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -11,250,000 0 -100.00
2017-02-03 2017-02-01 4 JNCE Jounce Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -35,750,000 0 -100.00
2017-02-03 2017-02-01 4 JNCE Jounce Therapeutics, Inc.
Common Stock
C - Conversion 3,048,780 3,048,780
2017-02-03 2017-02-01 4 JNCE Jounce Therapeutics, Inc.
Common Stock
C - Conversion 9,688,344 10,230,349 1,787.50
2017-01-26 3 JNCE Jounce Therapeutics, Inc.
Common Stock
1,084,010
2017-01-26 3 JNCE Jounce Therapeutics, Inc.
Common Stock
1,084,010
2017-01-26 3 JNCE Jounce Therapeutics, Inc.
Common Stock
1,084,010
2017-01-26 3 JNCE Jounce Therapeutics, Inc.
Common Stock
1,084,010
2017-01-26 3 JNCE Jounce Therapeutics, Inc.
Common Stock
1,084,010
2017-01-26 3 JNCE Jounce Therapeutics, Inc.
Common Stock
1,084,010
2017-01-26 3 JNCE Jounce Therapeutics, Inc.
Common Stock
1,084,010
2017-01-26 3 JNCE Jounce Therapeutics, Inc.
Common Stock
1,084,010
2017-01-26 3 JNCE Jounce Therapeutics, Inc.
Common Stock
1,084,010
2016-12-16 2016-12-14 4 GBT Global Blood Therapeutics, Inc.
Common Stock
J - Other X -2,000,000 7,475,191 -21.11
2016-12-01 2016-11-29 4 MYOK MyoKardia Inc
Common Stock
J - Other X -850,000 8,537,754 -9.05
2016-11-16 2016-11-14 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale -1,000,000 1,939,449 -34.02 19.36 -19,360,000 37,547,733
2016-11-16 2016-11-14 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale -1,000,000 1,285,713 -43.75 19.36 -19,360,000 24,891,404
2016-11-07 2016-11-03 4 GBT Global Blood Therapeutics, Inc.
Common Stock
J - Other -2,000,000 10,475,191 -16.03
2016-08-19 2016-08-19 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -1,000,000 2,892,916 -25.69
2016-05-18 2016-05-16 4 SAGE Sage Therapeutics, Inc.
Common Stock
S - Sale -850,000 3,892,916 -17.92 31.25 -26,562,500 121,653,625
2016-04-15 2016-04-14 4 BPMC Blueprint Medicines Corp
Common Stock
J - Other -1,200,000 5,453,753 -18.03
2015-11-18 2015-11-18 4 BPMC Blueprint Medicines Corp
Common Stock
J - Other 40,290 40,290
2015-11-18 2015-11-18 4 BPMC Blueprint Medicines Corp
Common Stock
J - Other 40,290 40,290
2015-11-18 2015-11-18 4 BPMC Blueprint Medicines Corp
Common Stock
J - Other 40,290 40,290
2015-11-18 2015-11-18 4 BPMC Blueprint Medicines Corp
Common Stock
J - Other -220,387 0 -100.00
2015-11-18 2015-11-18 4 BPMC Blueprint Medicines Corp
Common Stock
J - Other 220,387 220,387
2015-11-18 2015-11-18 4 BPMC Blueprint Medicines Corp
Common Stock
J - Other -739,306 6,653,753 -10.00
2015-11-13 2015-11-12 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 15,986 65,227 32.46
2015-11-13 2015-11-12 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 15,986 65,227 32.46
2015-11-13 2015-11-12 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -109,832 0 -100.00
2015-11-13 2015-11-12 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 109,832 109,832
2015-11-13 2015-11-12 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -1,700,000 4,742,916 -26.39
2015-11-05 2015-11-03 4 MYOK MyoKardia Inc
Series A Preferred Stock
C - Conversion -5,500,000 0 -100.00
2015-11-05 2015-11-03 4 MYOK MyoKardia Inc
Series A Preferred Stock
C - Conversion -32,500,000 0 -100.00
2015-11-05 2015-11-03 4 MYOK MyoKardia Inc
Common Stock
C - Conversion 1,496,598 1,496,598
2015-11-05 2015-11-03 4 MYOK MyoKardia Inc
Common Stock
C - Conversion 8,843,537 9,387,754 1,625.00
2015-10-28 3 MYOK MyoKardia Inc
Common Stock
1,088,434
2015-10-28 3 MYOK MyoKardia Inc
Common Stock
1,088,434
2015-10-28 3 MYOK MyoKardia Inc
Common Stock
1,088,434
2015-10-28 3 MYOK MyoKardia Inc
Common Stock
1,088,434
2015-10-28 3 MYOK MyoKardia Inc
Common Stock
1,088,434
2015-10-28 3 MYOK MyoKardia Inc
Common Stock
1,088,434
2015-10-28 3 MYOK MyoKardia Inc
Common Stock
1,088,434
2015-10-28 3 MYOK MyoKardia Inc
Common Stock
1,088,434
2015-10-28 3 MYOK MyoKardia Inc
Common Stock
1,088,434
2015-08-19 2015-08-17 4 GBT Global Blood Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -41,663,168 0 -100.00
2015-08-19 2015-08-17 4 GBT Global Blood Therapeutics, Inc.
Common Stock
C - Conversion 11,903,763 12,475,191 2,083.16
2015-08-18 2015-08-18 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 21,910 49,241 80.17
2015-08-18 2015-08-18 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 21,910 49,241 80.17
2015-08-18 2015-08-18 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -150,546 0 -100.00
2015-08-18 2015-08-18 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 150,546 150,546
2015-08-18 2015-08-18 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -2,330,157 6,442,916 -26.56
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1,142,856
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1,142,856
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1,142,856
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1,142,856
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1,142,856
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1,142,856
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1,142,856
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1,142,856
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1,142,856
2015-06-22 2015-06-19 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 9,403 27,331 52.45
2015-06-22 2015-06-19 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 9,402 27,330 52.44
2015-06-22 2015-06-19 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -64,607 0 -100.00
2015-06-22 2015-06-19 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 64,607 64,607
2015-06-22 2015-06-19 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -1,000,000 8,773,073 -10.23
2015-05-12 2015-05-05 4 BPMC Blueprint Medicines Corp
Series C Preferred Stock
C - Conversion -1,328,502 0 -100.00
2015-05-12 2015-05-05 4 BPMC Blueprint Medicines Corp
Series B Preferred Stock
C - Conversion -7,833,333 0 -100.00
2015-05-12 2015-05-05 4 BPMC Blueprint Medicines Corp
Series A Preferred Stock
C - Conversion -30,000,000 0 -100.00
2015-05-12 2015-05-05 4 BPMC Blueprint Medicines Corp
Common Stock
C - Conversion 241,545 7,393,059 3.38
2015-05-12 2015-05-05 4 BPMC Blueprint Medicines Corp
Common Stock
C - Conversion 1,424,242 7,151,514 24.87
2015-05-12 2015-05-05 4 BPMC Blueprint Medicines Corp
Common Stock
C - Conversion 5,454,545 5,727,272 2,000.00
2015-04-29 3 BPMC Blueprint Medicines Corp
Common Stock
545,454
2015-04-29 3 BPMC Blueprint Medicines Corp
Common Stock
545,454
2015-04-29 3 BPMC Blueprint Medicines Corp
Common Stock
545,454
2015-04-29 3 BPMC Blueprint Medicines Corp
Common Stock
545,454
2015-04-29 3 BPMC Blueprint Medicines Corp
Common Stock
545,454
2015-04-29 3 BPMC Blueprint Medicines Corp
Common Stock
545,454
2015-04-29 3 BPMC Blueprint Medicines Corp
Common Stock
545,454
2015-01-28 2015-01-27 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -81,094 0 -100.00
2015-01-28 2015-01-27 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 81,094 81,094
2015-01-28 2015-01-27 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -1,255,177 9,773,073 -11.38
2015-01-20 2015-01-16 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -42,173 0 -100.00
2015-01-20 2015-01-16 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other 42,173 42,173
2015-01-20 2015-01-16 4 SAGE Sage Therapeutics, Inc.
Common Stock
J - Other -652,758 11,028,250 -5.59
2014-07-23 2014-07-23 4 SAGE Sage Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -295,194 0 -100.00
2014-07-23 2014-07-23 4 SAGE Sage Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -2,499,999 0 -100.00
2014-07-23 2014-07-23 4 SAGE Sage Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -32,500,000 0 -100.00
2014-07-23 2014-07-23 4 SAGE Sage Therapeutics, Inc.
Common Stock
C - Conversion 93,712 11,681,008 0.81
2014-07-23 2014-07-23 4 SAGE Sage Therapeutics, Inc.
Common Stock
C - Conversion 793,650 11,587,296 7.35
2014-07-23 2014-07-23 4 SAGE Sage Therapeutics, Inc.
Common Stock
C - Conversion 10,317,457 10,793,646 2,166.67
2014-07-17 3 SAGE Sage Therapeutics, Inc.
Common Stock
952,378
2014-07-17 3 SAGE Sage Therapeutics, Inc.
Common Stock
952,378
2014-07-17 3 SAGE Sage Therapeutics, Inc.
Common Stock
952,378
2014-07-17 3 SAGE Sage Therapeutics, Inc.
Common Stock
952,378
2014-07-17 3 SAGE Sage Therapeutics, Inc.
Common Stock
952,378
2014-07-17 3 SAGE Sage Therapeutics, Inc.
Common Stock
952,378
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)